Poseida Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-123.43	-64	-124.97	-129.78	-86.53	-44.4
Depreciation & Amortization	5.61	5.17	4.55	2.59	1.19	0.69
Share-Based Compensation	23.13	18.93	16.7	7.22	3.05	0.98
Other Operating Activities	2.52	13.13	1.18	6.64	17.77	4.73
Operating Cash Flow	-92.17	-26.77	-102.54	-113.33	-64.52	-38.01
Capital Expenditures	-3.07	-3.91	-2.62	-16.91	-5.16	-1.28
Change in Investments	42.2	-199.42	225	-187.52	-37.31	0
Investing Cash Flow	39.13	-203.33	222.38	-204.43	-42.46	-1.28
Share Issuance / Repurchase	15.35	75.3	0	310.11	149.78	30.57
Debt Issued / Paid	0	28.55	0	-0.33	9.95	9.41
Other Financing Activities	0.78	1.31	2.52	4.16	4.64	14.1
Financing Cash Flow	16.13	105.16	2.52	313.94	164.37	54.07
Net Cash Flow	-36.91	-124.95	122.36	-3.82	57.39	14.77
Free Cash Flow	-95.23	-30.68	-105.16	-130.24	-69.67	-39.3
Free Cash Flow Margin	-147.18%	-23.51%	-336.64%	-	-	-
Free Cash Flow Per Share	-1.06	-0.43	-1.69	-3.62	-5.52	-3.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).